Intravitreal Aflibercept Treatment Strategies in Routine Clinical Practice of Neovascular Age-Related Macular Degenerati
- PDF / 692,991 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 72 Downloads / 186 Views
ORIGINAL RESEARCH
Intravitreal Aflibercept Treatment Strategies in Routine Clinical Practice of Neovascular AgeRelated Macular Degeneration in Belgium: A Retrospective Observational Study Joke Ruys . Els Mangelschots . Julie Jacob . Filip Mergaerts . Alexandra Kozyreff . Werner Dirven
Received: July 22, 2020 / Accepted: September 3, 2020 Ó The Author(s) 2020
ABSTRACT Introduction: STELLAR was a Belgian, multicentre, retrospective, observational chart review that described the utilization (number of injections and treatment regimen) and effectiveness of intravitreal aflibercept (IVT-AFL) in patients Digital Features To view digital features for this article go to https://doi.org/10.6084/m9.figshare.12906812. Electronic supplementary material The online version of this article (https://doi.org/10.1007/s40123020-00300-7) contains supplementary material, which is available to authorized users. J. Ruys (&) Department of Ophthalmology, ZNA Middelheim, Antwerp, Belgium e-mail: [email protected] E. Mangelschots Oogartsenpraktijk Alken, Alken, Belgium J. Jacob Department of Ophthalmology, UZ Leuven, Leuven, Belgium F. Mergaerts Oogartsenpraktijk Scherpenheuvel, Aarschot, Belgium A. Kozyreff Department of Ophthalmology, Cliniques Universitaires de Saint-Luc, Brussels, Belgium W. Dirven Department of Ophthalmology, AZ Turnhout, Turnhout, Belgium
with anti-vascular endothelial growth factor (VEGF) treatment-naı¨ve neovascular age-related macular degeneration (nAMD) during the first 12 months of IVT-AFL treatment. Methods: Patients initiating IVT-AFL between July 2013 and July 2017 were included in STELLAR. Primary endpoints were number of visits and IVT-AFL injections, and number of patients who received C 7 versus \ 7 IVT-AFL injections during the first 12 months of treatment. Results: A total of 337 patients completed C 12 months of IVT-AFL treatment. The mean number of visits and mean number of injections during the first 12 months was 9.8 and 7.1 injections, respectively (64% received C 7 injections). Overall, 96% of patients received C 3 initial monthly injections. Of the 337 patients, 180 received VTAFL as needed (pro re nata), 141 received it as treatand-extend dosing and 16 received it as fixed dosing. The proportion of patients who received treatand-extend dosing increased year-on-year. Mean best-corrected visual acuity (BCVA) (± standard deviation) was 61.6 (± 14.9) Early Treatment Diabetic Retinopathy Study (ETDRS) letters at baseline and improved by ? 3.9 and ? 5.7 ETDRS letters at 3 and 12 months, respectively. Mean BCVA improvement was numerically greater in patients who received C 7 versus \7 injections during the first 12 months 7 (? 6.5 vs. ? 4.4 ETDRS letters) and in patients who received C 3 versus \ 3 initial monthly injections (? 5.2 vs. - 0.25 ETDRS letters [3 at months]; ? 5.9 vs ? 1.2 ETDRS letters [at 12 months]). No specific adverse events were reported.
Ophthalmol Ther
Conclusion: Most patients in this Belgian study received C 7 IVT-AFL injections during a mean of 9.8 visits over the 12 months
Data Loading...
